Risk-Association of CYP11A1 Polymorphisms and Breast Cancer Among Han Chinese Women in Southern China by Sun, Minying et al.
Int. J. Mol. Sci. 2012, 13, 4896-4905; doi:10.3390/ijms13044896 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Article 
Risk-Association of CYP11A1 Polymorphisms and Breast 
Cancer Among Han Chinese Women in Southern China 
Minying Sun 
1,†, Xuexi Yang 
1,†, Changsheng Ye 
2, Weiwen Xu 
1, Guangyu Yao 
2, Jun Chen 
2 and 
Ming Li 
1,3,* 
1  School of Biotechnology, Southern Medical University, Guangzhou 510515, China;  
E-Mails: sunmy1220@163.com (M.S.); yxxzb@sohu.com (X.Y.); xu_sandy2006@126.com (W.X.) 
2  Breast Center, Nanfang hospital, Southern Medical University, Guangzhou 510515, China;  
E-Mails: Yechsh2006@126.com (C.Y.); ygy531@163.com (G.Y.); chenjunlqq@163.com (J.C.) 
3  Da An Gene Co., Ltd. of Sun Yat-sen University, Guangzhou 510665, China  
†  These authors contributed equally to this work. 
*  Author to whom correspondence should be addressed; E-Mail: mingli2006_2006@126.com;  
Tel.: +86-20-61648550; Fax: +86-20-61648554.  
Received: 13 January 2012; in revised form: 20 March 2012 / Accepted: 26 March 2012 /  
Published: 18 April 2012  
 
Abstract: Exposure to endogenous sex hormones has been reported as a risk factor for 
breast cancer. The CYP11A1 gene encodes the key enzyme that catalyzes the initial and 
rate-limiting  step  in  steroid  hormone  synthesis.  In  this  study,  the  associations  between 
single nucleotide polymorphisms (SNPs) in CYP11A1 and breast cancer susceptibility were 
examined. Six SNPs in CYP11A1 were genotyped using the MassARRAY IPLEX platform 
in 530 breast cancer patients and 546 healthy controls. Association analyses based on a χ
2 
test and binary logistic regression were performed to determine the odds ratio (OR) and 
95% confidence interval (95% CI) for each SNP. Two loci (rs2959008 and rs2279357) 
showed evidence of associations with breast cancer risk. The variant genotype C/T-C/C of 
rs2959008 was significantly associated with a decreased risk (age-adjusted OR, 0.75; 95% 
CI, 0.58–0.96; P = 0.023) compared with the wild-type TT. However, the homozygous TT 
variant of rs2279357 exhibited increased susceptibility to breast cancer (age-adjusted OR, 
1.44; 95% CI, 1.05–1.98; P = 0.022). The locus rs2959003 also showed an appreciable 
effect, but no associations were observed for three other SNPs. Our results suggest that 
polymorphisms  of  CYP11A1 are  related to  breast  cancer susceptibility in  Han Chinese 
women of South China. 
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1. Introduction 
Breast cancer is one of the most common malignancies among women worldwide and the incidence 
rate is increasing. Compared with Western countries, the peak age of breast cancer incidence is much 
earlier and the mortality rate is increasing in Asian populations [1]. Breast cancer is a heterogeneous 
disease caused by multiple genetic and environmental factors. Many candidate genes that may cause 
breast cancer have been identified in the past few years including high penetrance genes (BRCA1/2, 
TP53 and PTEN), moderate penetrance genes (ATM, CHEK2, PALB2 and BRIP), and low penetrance 
genes (FGFR2, ESR1 and TOX3) [2–7]. Inherited mutations among those genes predispose to high 
risks of breast cancer. Life time risks of breast cancer among BRCA1/2 mutation carriers are 82% [8]. 
Mutations of CHEK2, PALB2, and BRIP1 have a 2.34, 2.3, and 2.0 fold increase risk for breast cancer 
compared to the normal population, respectively [5–7]. Numerous genome-wide association studies 
(GWAS) also have identified approximately fifty common genetic loci for breast cancer risk in low 
penetrance genes such as FGFR2, ESR1, LSP1, MAP3K1, RAD51L1 and TOX3 [9–13]. Although each 
locus confers no more than 1.4 odds ratio, a combination of these variants may act cumulatively to 
increase  breast  cancer  risk.  As  more  breast  cancer  susceptibility  genes  of  different  penetrances  are 
identified, more appropriate genetic tests and risk reduction strategies can be developed. 
Previous  reports  indicate  that  prolonged  exposure  to  endogenous  sex  hormones,  especially 
estrogens and progestogens, can increase the risk of breast cancer [14,15]. High levels of endogenous 
sex  hormones  are  considered  crucial  factors  associated  with  breast  cancer  susceptibility.  Several  
case-control studies have also shown evidences that polymorphisms in steroid hormone biosynthesis 
genes are associated with breast cancer susceptibility [16–19]. The CYP11A1 (cytochrome P-450 11A1) 
gene is located at 15q23-q24 and consists of nine exons spanning a total of 29,864 bp. This gene 
encodes  the  cholesterol  side  chain  cleavage  enzyme  P450scc,  a  member  of  the  cytochrome  P450 
superfamily  of  enzymes,  which  resides  on  the  mitochondrial  inner  membrane  and  catalyzes  the 
conversion  of  cholesterol  to  pregnenolone,  the  initial  and  rate-limiting  step  in  steroid  hormone 
synthesis [20]. CYP11A1 is primarily expressed in steroidogenic tissues, such as the adrenal cortex, 
gonads, and placenta. Although P450scc is always active, genetic variants of CYP11A1 may alter its 
expression  and  activities,  and  thus  result  in  certain  hormone-related  diseases.  Polymorphisms  of 
CYP11A1 have been detected as potential markers in different hormone-dependent diseases, including 
breast  cancer  [16–19],  polycystic  ovary  syndrome  (PCOS)  [21],  prostate  cancer  [22,23],  and 
endometrial cancer [24]. Genetic architecture is different among populations and the data reported to 
date concentrate mainly on Western populations or pentanucleotide [(TAAAA)n] repeat polymorphisms. 
Here, we investigated the associations between single nucleotide polymorphisms (SNPs) in CYP11A1 
and breast cancer among Han Chinese women in Guangdong province, South China. Six SNPs in 
CYP11A1  (rs2959008,  rs2959003,  rs2279357,  rs11638442,  rs2073475,  and  rs16968478)  were 
genotyped to perform a case-control study in women from Guangdong province. Int. J. Mol. Sci. 2012, 13  4898 
 
2. Results and Discussion 
2.1. Study Subjects 
All subjects included in this study were Han Chinese women. The mean ages of the patients and 
controls  were  48.48  ±   10.18  and  44.59  ±   11.26  years,  respectively.  An  independent-sample  t-test 
indicated a significant difference in age distribution between the two groups (P < 0.05, data not shown), 
so all statistical analyses were subsequently adjusted by age. 
2.2. Hardy-Weinberg Equilibrium (HWE), Linkage Disequilibrium (LD) and Haplotype Analysis 
All  SNPs  conformed  to  Hardy-Weinberg  equilibrium  (HWE)  among  both  cases  and  controls  
(P > 0.05) with minor allele frequency (MAF) ≥ 0.22 (Table 1). The SNPs rs11638442, rs2073475, 
and rs16968478 were in high or complete linkage disequilibrium as well as rs2959003 and rs2279357 
(supplementary  material).  D’  values  are  shown  in  Figure  1.  The  SNP  rs2959008  had  a  low  LD 
compared to the others. 
Table 1. Genotype characteristics of the six single nucleotide polymorphisms (SNPs). 
SNP  Alleles  MAF
a 
HWE
b (P-value) 
Case  Control 
rs2959008  C/T  0.36/C  0.976  0.587 
rs2959003  C/T  0.38/C  0.852  0.519 
rs2279357  C/T  0.43/T  0.403  0.803 
rs11638442  C/G  0.22/G  0.659  0.674 
rs2073475  A/G  0.44/A  0.951  0.765 
rs16968478  A/G  0.46/G  0.834  0.732 
a Minor Allele Frequency; 
b Hardy-Weinberg equilibrium. 
Figure 1. Linkage disequilibrium (LD) pattern among six SNPs by Haploview analysis. 
Numbers inside the boxes represent D’ values for LD, and the miss number is 100. 
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Six main haplotypes of CYP11A1 were considered in the analysis for all subjects. The results of 
individual haplotype analysis and breast cancer are shown in Table 2. The haplotype TTTCAG was 
most common in both case and control groups. The distribution frequency of haplotype CCCCGA was 
significantly different between the two groups and protective against the development of breast cancer 
(OR, 0.64; 95% CI, 0.48–0.86; P = 0.0033). 
Table 2. Association between haplotypes and breast cancer for six SNPs in CYP11A1. 
Haplotype
a 
Frequencies 
OR (95% CI)
b  P-value 
Total  Control  Case 
TTTCAG  0.2936  0.2755  0.314  1  - 
CCCGGA  0.153  0.1567  0.1495  0.82 (0.62–1.08)  0.15 
CCCCGA  0.1309  0.1495  0.1111  0.64 (0.48–0.86)  0.0033 
TTCCAG  0.1273  0.1333  0.1203  0.78 (0.58–1.06)  0.11 
TTTCGA  0.1177  0.1079  0.1269  1.03 (0.76–1.40)  0.83 
TCCCGA  0.0673  0.071  0.0638  0.83 (0.57–1.20)  0.32 
rare  0.1102  0.1061  0.1145  0.92 (0.67–1.28)  0.64 
a  Haplotypes  were  constructed  for  rs2959008,  rs2959003,  rs2279357,  rs11638442,  rs2073475  and 
rs16968478; 
b OR (95% CI) was adjusted for age and the bold values indicate P < 0.05.  
2.3. Polymorphisms of CYP11A1 and Breast Cancer Risk 
The genotype distributions of rs2959008 and rs2279357 were significantly different between cases 
and controls in the chosen genetic model (Table 3). For rs2959008, the variant genotype C/T-C/C was 
significantly  associated  with  a  decreased  risk  of  breast  cancer  (OR,  0.75;  95%  CI,  0.58–0.96;  
P = 0.023) compared with the wild-type TT. Individuals carrying the C allele showed protection from 
breast cancer (OR, 0.80; 95% CI, 0.67–0.96; P = 0.018). In contrast to rs2959008, the homozygous TT 
variant  and  allele  T  of  rs2279357  were  associated  with  elevated  susceptibility  to  breast  cancer  
(OR, 1.44; 95% CI, 1.05–1.98; P = 0.022 and OR, 1.23; 95% CI, 1.04–1.47; P = 0.018, respectively). 
A correlation between the rs2959003 polymorphism and breast cancer was also observed under the 
log-additive  model.  Three  other  SNPs  (rs11638442,  rs2073475,  and  rs16968478)  did  not  show 
significant differences between the groups in the present study (supplementary material). 
A further association analysis was conducted to identify the interactions of two susceptibility-associated 
SNPs, rs2959008 and rs2279357, and their impact on the risk of breast cancer. The results indicated that 
the united genotype TT-TT of rs2959008 and rs2279357 showed increased breast cancer risk (OR, 
1.65;  95%  CI,  1.18–2.31;  P  =  0.003)  (Table  4).  There  was  also  a  marginal  association  between 
genotype CT/CC-TT and reduced breast cancer risk (OR, 0.12; 95% CI, 0.02–0.94; P = 0.044). 
Breast cancer risk is partially determined by endogenous hormone levels [25]. Given the important 
role of P450scc in steroid sex hormone biosynthesis, this case-control study was performed among 
Han  Chinese  women  in  Guangdong  province.  All  six  SNPs  (rs2959008,  rs2959003,  rs2279357, 
rs11638442, rs2073475 and rs16968478) are located in noncoding regions of CYP11A1, with the first 
four  in  introns  and  the  latter  two  upstream  of  the  gene.  The  results  showed  that  rs2959008  and 
rs2279357 of the  CYP11A1 gene  were strongly associated  with  breast  cancer risk,  as  well  as  the 
interaction of the two SNPs. Int. J. Mol. Sci. 2012, 13  4900 
 
Table 3. The genotype distributions (%) and association of breast cancer risk. 
SNP  Model  Genotype  Control  Case  OR (95% CI)
 a  P-value 
rs2959008 
Codominant 
T/T  205 (37.5%)  229 (43.2%)  1 
0.057    C/T  264 (48.4%)  239 (45.1%)  0.77 (0.59–1.00) 
  C/C  77 (14.1%)  62 (11.7%)  0.67 (0.45–0.99) 
 
Dominant 
T/T  205 (37.5%)  229 (43.2%)  1 
0.023 
  C/T-C/C  341 (62.5%)  301 (56.8%)  0.75 (0.58–0.96) 
 
Recessive 
T/T-C/T  469 (85.9%)  468 (88.3%)  1 
0.16 
  C/C  77 (14.1%)  62 (11.7%)  0.77 (0.53–1.11) 
 
Overdominant 
T/T-C/C  282 (51.6%)  291 (54.9%)  1 
0.2 
  C/T  264 (48.4%)  239 (45.1%)  0.85 (0.67–1.09) 
  Log-additive  -  -  -  0.80 (0.67–0.96)  0.018 
rs2959003 
Codominant 
T/T  196 (36%)  218 (41.3%)  1 
0.092    C/T  255 (46.9%)  241 (45.6%)  0.84 (0.64–1.10) 
  C/C  93 (17.1%)  69 (13.1%)  0.67 (0.46–0.97) 
 
Dominant 
T/T  196 (36%)  218 (41.3%)  1 
0.072 
  C/T-C/C  348 (64%)  310 (58.7%)  0.79 (0.62–1.02) 
 
Recessive 
T/T-C/T  451 (82.9%)  459 (86.9%)  1 
0.078 
  C/C  93 (17.1%)  69 (13.1%)  0.74 (0.52–1.04) 
 
Overdominant 
T/T-C/C  289 (53.1%)  287 (54.4%)  1 
0.62 
  C/T  255 (46.9%)  241 (45.6%)  0.94 (0.74–1.20) 
  Log-additive  -  -  -  0.82 (0.69–0.98)  0.03 
rs2279357 
Codominant 
C/C  193 (35.4%)  164 (30.9%)  1 
0.048    C/T  265 (48.6%)  253 (47.7%)  1.14 (0.87–1.50) 
  T/T  87 (16%)  113 (21.3%)  1.56 (1.09–2.22) 
 
Dominant 
C/C  193 (35.4%)  164 (30.9%)  1 
0.1 
  C/T-T/T  352 (64.6%)  366 (69.1%)  1.24 (0.96–1.61) 
 
Recessive 
C/C-C/T  458 (84%)  417 (78.7%)  1 
0.022 
  T/T  87 (16%)  113 (21.3%)  1.44 (1.05–1.98) 
 
Overdominant 
C/C-T/T  280 (51.4%)  277 (52.3%)  1 
0.82 
  C/T  265 (48.6%)  253 (47.7%)  0.97 (0.76–1.24) 
  Log-additive  -  -  -  1.23 (1.04–1.47)  0.018 
a OR (95% CI) was adjusted for age and the bold values indicate P < 0.05. 
Table 4. Interaction for rs2959008 and rs2279357 between case and control group. 
Genotype  Control  Case  χ
2   P-value  OR (95% CI)
a  P-value 
TT-TT  77 (14.1%)  112 (21.1%) 
15.57  0.001 
1.65 (1.18–2.31)  0.003 
TT-CT/CC  127 (23.3%)  117 (22.1%)  1.10 (0.81–1.48)  0.551 
CT/CC-TT  10 (1.8%)  1 (0.2%)  0.12 (0.02–0.94)  0.044 
CT/CC-CT/CC  331 (60.7%)  300 (56.6%)  1  - 
a OR (95% CI) was adjusted for age and the bold values indicate P < 0.05. 
Numerous studies have examined CYP11A1 gene polymorphisms. The best studied region is the 
pentanucleotide [TTTTA]n repeat (D15S520) located 528 bp upstream of the translational initiation 
site, which showed six common polymorphisms with four, six, seven, eight, nine, or ten [TTTTA] Int. J. Mol. Sci. 2012, 13  4901 
 
repeats. In the Chinese population, the main variants are the four-, six-, and eight-repeat alleles, which 
are correlated with risks of breast cancer [16,17] and polycystic ovarian syndrome [21]. The [TTTTA]4 
and  [TTTTA]6  alleles  were  also  shown  to  be  associated  with  prostate  cancer  in  other  ethnic  
groups  [22,23].  However,  the  [(TAAAA)n]  polymorphism  was  different  from  common  biallelic 
variations in the present study. 
Setiawan  et  al.  systematically  evaluated  genetic  variations  spanning  67  kb  of  CYP11A  and 
suggested  that  common  variations  in  CYP11A  may  be  related  to  breast  cancer  susceptibility  in  a 
western Multiethnic Cohort Study, but no particular SNP or haplotype was identified as the most likely 
causal variant [18]. Mammographic density has also been shown to be a breast cancer risk factor, and 
is strongly associated with hormone exposure profile [26]. In Swedish women, our five tag SNPs 
(rs2959008,  rs2959003,  rs2279357,  rs11638442,  and  rs16968478)  were  significantly  related  to 
mammographic density in single SNP analysis, but the relationship disappeared after correction for 
multiple  testing  [27].  Another  three  tag  SNPs  (rs4555110,  rs3825944,  and  rs7173655)  were 
significantly associated with increased (1.3–1.4-fold) endometrial cancer risk in women in Boston, 
USA  [24].  Along  with  another  11  loci,  polymorphisms  of  CYP11A1  were  also  confirmed  to  be 
associated with hypertension and blood pressure (BP) in the Japanese population, with the presence of 
more  of  these  alleles  indicating  higher  risk  [28].  These  results  were  mainly  based  on  Western 
populations. Haplotype analysis indicated that the promoter haplotype of CYP11A1 was associated 
with  increased  risk  of  breast  cancer  among  Chinese  women  in  Shanghai,  but  three  of  our  SNPs 
(rs2959008,  rs2959003,  and  rs16968478)  were  not  included  [19].  Here,  we  focused  on  the  Han 
Chinese population in Guangdong province and identified breast cancer-related SNPs. Six SNPs that 
have seldom been reported in the Han Chinese population were selected to verify the association. The 
results suggested that the haplotype CCCCGA had a protective effect against breast cancer. Two single 
SNPs, rs2959008 and rs2279357, were significantly associated with breast cancer risk and interaction 
analysis also demonstrated that the united genotype TT-TT of these two SNPs showed much higher 
risk of breast cancer. 
3. Experimental Section  
3.1. Subjects 
The subjects participated in our study were recruited between April 2009 and October 2011 from 
Nanfang  Hospital,  Southern  Medical  University,  Guangzhou,  Guangdong  Province,  China.  All 
participants  were  permanent  residents  of  Guangdong  from  the  Han  Chinese  population.  Clinical 
information for each subject was collected from medical records. 
3.1.1. Patients of Breast Cancer 
A total of 621 female patients with breast cancer were recruited after confirmed by pathological 
diagnosis through breast clinics. 550 (88.6%) of them were approached with their written informed 
consent and blood samples were collected. The age ranged from 22 to 80 years old. Other 71 patients 
refused to provide blood samples. Blood samples from 14 patients were unusable for DNA extraction Int. J. Mol. Sci. 2012, 13  4902 
 
due to transportation and storage at −70 °C  After genotyping, 6 samples were excluded as all six SNPs 
could not be determined. Therefore, 530 case subjects were included in the final statistical analysis. 
3.1.2. Controls 
550 healthy control women were randomly selected from outpatients ranging in age from 16 to  
84 years old during the same period with no history of cancer or other breast-related diseases as 
determined  by  molybdenum  target  mammography  and  color  Doppler  ultrasonography  and  blood 
samples  were  collected.  However,  4  samples  failed  in  genotyping  and  546  healthy  controls  were 
included in the final statistical analysis. 
The study protocol was approved by the Clinical Research Ethics Committee of Nanfang Hospital 
and written informed consent was obtained from all participants. 
3.2. DNA Extraction 
Peripheral blood samples were collected from the participants and stored at  −70 °C until DNA 
extraction. Genomic DNA was extracted from peripheral blood samples using an E.Z.N.A.™ blood 
DNA kit (Omega Bio-Tek, Norcross, GA, USA) according to the manufacturer’s protocol. 
3.3. Genotyping 
For each SNP, a pair of amplification primers and an extension primer was designed using Assay 
Design  3.1  software  (Sequenom,  San  Diego,  CA,  USA).  Genotypes  were  generated  using  the 
SEQUENOM MassARRAY matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) 
mass  spectrometry  platform  (Sequenom,  San  Diego,  CA,  USA)  according  to  the  manufacturer’s 
instructions. This is one of the most powerful tools for detecting insertions, deletions, substitutions, 
and other polymorphisms in amplified DNA, and allows rapid, efficient, and high-throughput detection 
without any interactions. The overall call rates ranged from 99.63% to 100%. 
3.4. Statistical Analysis 
Hardy–Weinberg  equilibrium  (HWE)  and  linkage  disequilibrium  (LD)  for  the  six  SNPs  were 
calculated  using  Haploview  4.2  (Daly  Lab,  Cambridge,  MA,  USA).  The  genotype  and  allele 
distributions as well as the interactions of SNPs between case and control subjects were compared. 
Multiple inheritance models (codominant, dominant, recessive, overdominant, and log-additive) were 
chosen to evaluate the associations between each SNP and breast cancer risk. The odds ratio (OR) and 
95% confidence interval (95% CI) were evaluated by binary logistic regression analyses. There was a 
significant difference in age distribution between case and control groups as described previously, so 
the age was adjusted by setting as a covariate in association analyses for each SNP. Statistical analyses 
were  implemented  using  SPSS  13.0  software  (SPSS,  Chicago,  IL,  USA)  and  the  Web-based  tool 
SNPstats [29]. All comparisons were two-sided and P < 0.05 was regarded as statistically significant. 
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4. Conclusions  
In  summary,  our  results  showed  that  rs2959008  and  rs2279357  of  the  CYP11A1  gene  were 
significantly associated with breast cancer susceptibility among Guangdong Han Chinese women, and 
the interaction of these two SNPs was associated with elevated risk. The haplotype CCCCGA of our 
six  SNPs  also  had  a  protective  effect  against  the  development  of  breast  cancer.  The  biological 
mechanisms  behind  these  associations  remain  unknown.  Therefore,  further  comprehensive 
investigations of steroid hormone biosynthesis and metabolism gene variations combined with other 
risk factors are required to identify biomarkers for inherited breast cancer susceptibility. 
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